Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Yesterday's online article in the Guardian titled
'From flying taxis to painless vaccines: Seven businesses to watch this year'
is on page 51 of today's Sunday Observer.
The only difference in the printed version, is the ommitance of the sentence
' and data from the studies is expected by June.'
Let's hope this means we get the data earlier
https://www.pressreader.com/uk/the-observer/20220102/282484302100238
Scancell's selection of pharmajet has been uploaded today by Drug Delivery Business News as one of their favourite articles of 2021.
https://www.youtube.com/watch?v=YTqqTRw5QQo
Last weekend's article by Julia Kollewe is on page 18 in today's Guardian Weekly Magazine.
The Guardian Weekly is over a hundred years old and is one of the world's oldest international news publications and has readers in more than 170 countries.
https://www.pressreader.com/uk/the-guardian-weekly/20211217/281479279720149
Julia Kollewe’s excellent article is on page 28 in this morning’s Australian Guardian and page 30 in today’s Guardian USA .
https://www.pressreader.com/search?query=Scancell
A slightly shortened version of yesterday’s excellent online article by Julia Kollewe is on page 59 of today’s Observer.
Two sections of the article that mention Scancell are,
‘So what do we know about the new covid-19 covid vaccines. One change about the delivery mechanisms, such as San Francisco firm Vaxarts vaccine in-a-pill and Scancell’s spring powered injectors that pierce the skin without a needle.’
‘Scancell
The spin out from the University of Nottingham is testing two vaccines that induce antibody and T cell responses. They are given via needle-free injectors that use a narrow stream of fluid to penetrate the skin.
Founded in 1997 by Lindy Durrant, professor of cancer immunotherapy at Nottingham University, Scancell specialises in cancer vaccines. It listed in London in 2008.’
There is also a photo of Scancell’s needle free system in the Observer.
Introducing Scancell's new facilities.
https://www.scancell.co.uk/latest-news
Good publicity today from Business wire.
https://www.businesswire.com/news/home/20210914005060/en/PharmaJet-selected-to-deliver-Scancell-COVID-19-DNA-Vaccines
MP Tom Hunt's question to Sajid Javid about Universal vaccine is at 1 hour 24 minutes.
https://youtu.be/zztdqHjj6VM
Today Seneca Growth (formally Hygea) gave an update to it's investors. Although there was no presentation from Scancell, they did get mentioned between 49 and 51 minutes.
https://senecavct.co.uk/september-2021-shareholder-update-presentation/
Lindy has just been interviewed on Proactive Investors.
https://www.proactiveinvestors.co.uk/companies/news/958824/scancell-holdings--professor-lindy-durrant-presents-cancer-vaccine-candidate-modi-1-trial-plan-958824.html
A pinned tweet is an important tweet that remains at the top of a Twitter feed.
After almost a year, today Scancell has changed their pinned tweet to
'Scancell Holdings plc to use needle-free technology for next generation vaccine candidates'
In my opinion this shows they have a great deal of confidence in the upcoming trials.
https://www.proactiveinvestors.co.uk/companies/amp/news/957850?__twitter_impression=true
Yesterday's excellent online article by Hannah Boland is on page 27 of the business section in the Daily Telegraph.
British biotech company to test needle-free Covid jabs.
'A BRITISH biotech company is planning to introduce needle-free Covid-19 jabs in a bid to boost vaccine take-up by those wary of injections.
Scancell has struck a deal to use kit made by Pharmajet, a medical technology company, which penetrates the skin with a precise stream of fluid instead – getting vaccines into the body in a 10th of a second. The method will be used in forthcoming clinical trials for variant-busting Covid vaccines.
These spring-loaded systems save as much as 70pc of preparation and administration time compared with needles, Scancell said, with patients feeling a “snap like a rubber band when the injection is administered”.
In a study by the University of Oxford in June, around a quarter of adults screened positive for potential needle phobia. The booster campaign for vaccines is due to kick off next month, with those in more vulnerable groups given a third dose of the Covid vaccine.
Scancell, which is listed on the Aim junior stock market, is developing a “universal” Covid-19 vaccine intended to be variant-proof, meaning that patients would not need to get a tweaked version of existing jabs as the virus mutated.'
https://www.pressreader.com/uk/the-daily-telegraph/20210818/282540136411540
Last week's excellent article by Rachel Ellis titled, Super 'Universal' Vaccine to fight off any Corona virus.
is on page 6 in the health section of today's Irish Daily Mail.
https://www.pressreader.com/ireland/irish-daily-mail/20210810/281998970516663
Scancell is doing a video presentation on Wednesday 28th July 2.00pm at the OXT AGM.
https://www.investegate.co.uk/oxford-technology--oxt-/gnw/notice-of-agm-and-shareholder-presentations/20210722072604H7506/
British biotech Scancell Holdings PLC is embarking on a phase 1 trial of two next-generation vaccine candidates against COVID-19, which may not only offer improved protection against new variants of the virus but also provide an option for anyone afraid of needles.
The candidates, called SCOV1 and SCOV2, are based on Scancell's ImmunoBody DNA vaccine technology and have a dual mechanism of action targeting both the virus' highly conserved nucleocapsid N antigen and its more variable spike protein. Delivered via different needle-free options, the vaccines are designed to elicit a high level of virus-neutralizing antibodies that can cross-react against a range of COVID-19 variants of concern, including the Beta variant first identified in South Africa.
Due to the rapid rollout of the U.K. vaccination program, the first part of the clinical trial will take place in South Africa at the University of Cape Town Lung Institute, where it will be easier to recruit a pool of healthy adult volunteers who are still unvaccinated. The second part of the trial — intended to take place in the U.K. — will see SCOV2 administered to healthy volunteers who have already received two doses of an approved vaccine.
The immune responses from the second part of the study will allow Oxford, U.K.-based Scancell to see if SCOV2 can boost the immune response against current and potential future strains of COVID-19 in pre-vaccinated individuals.
"There is a significant threat from future mutations of the SARS-CoV-2 virus, as we have seen with the rapid transmission of the Delta variant," Scancell CEO Cliff Holloway said in a statement. "Our next-generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2."
https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/first-in-human-needle-free-vaccine-for-covid-variants-fabry-disease-therapy-65370024?utm_source=twitter&utm_medium=social&utm_term=d1561a26-b795-4752-a562-e5d48c6d07ad&utm_content=organic&utm_campaign=news
Drugs minnow Scancell shot higher after it announced it will start a phase one clinical trial of two of its potential covid vaccines.
https://www.pressreader.com/search?query=Scancell%20&languages=en&groupBy=Language&hideSimilar=0&type=1&state=1
Three new Scancell jobs have been advertised in today's New Scientist.
https://jobs.newscientist.com/en-gb/searchjobs/
Pan-coronavirus vaccine breakthrough in the fight against future pandemics .
In the UK, Scientists from the University of Nottingham and a company called Scancell are working to develop an mRNA-base jab specific to all Covid variants their vaccine targets the conserved core of SARS coV-2 called the nucleocapsid as well as the spike protein which is the main site of the mutations that have been detected to date.
Dr Gillies O'Bryan-Tear, Scancell chief medical officer,
"What's been mutated in the pandemic has been the spike protein, which alters the transmissibility of the virus and can alter it's ability to resist either the immunity required by natural infection or vaccination."
"The difference between our technology and most others is that as well as targeting the spike protein,we have another specificity in our vaccine which targets the nucleocapsid protein. This is the body of the virus.We don't think it mutates as much as the spike does so there's a chance it could work across different variants irrispective of the spike protein mutations."
Human trials of the vaccine will begin in the second half of this year after testing on mice returned positive results.
https://www.pressreader.com/uk/the-independent-1029/20210516/281651077996649
Lindy is speaking at the 4th Annual Next Gen Immuno-oncology Virtual Congress- US Edition.
June 28th to 30th 2021.
https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers
Another Scancell prediction from Zak Mir on around 9 minutes.
https://m.youtube.com/watch?v=_iu0yc6u84o
BBC Mundo is the BBC's service for the Spanish speaking world. It is part of the BBC world service.
'Can a universal vaccine be created that protects us against all Corona viruses?'
According to the magazine Science, currently in the world there are more than 20 research teams working on a candidate for a pancoronavirus vaccine.
'According to CEPI, several of these initiatives look promising in principle.
One of them is the colaboration between the University of Nottingham, Nottingham Trent University and the pharmaceutical company Scancell.
His bet is for a vaccine that acts on the spike protein and on another structure of the virus, called protein N.
This N protein is much less prone to mutating, so if the vaccine manages to act on it, it could generate an immune response regardless of whether the spike has mutated.
In that way, it could offer protection against various types of coronavirus.'
https://digismak.com/can-a-universal-vaccine-be-created-that-protects-us-against-all-coronaviruses/
https://www.bbc.com/mundo/noticias-56897149